Vandana Singh Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides HHS is considering major cuts to federal HIV prevention funding as part of a CDC ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

Gilead Sciences, Inc. GILD hit a 52-week high of $119.96 on March 10. The stock is currently trading at $111.44. Shares have also gained 5.5% in the past month compared with the industry’s ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by JP Morgan, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc happened on ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to December 2024, Gilead Sciences recorded an accrual ...

It has been about a month since the last earnings report for Gilead Sciences (GILD). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...